Last Update

This profile was last updated on 9/11/2017 and contains contributions from the  ZoomInfo Community.

is this you? Claim your profile.

Wrong Suzanne Robotti?

Suzanne B. Robotti

Executive Director

DES Action

HQ Phone:  (347) 754-7912

Direct Phone: (800) ***-****direct phone

Get Zoominfo Grow
Community Edition

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    the Plugin
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check Your Inbox to
    Sign Up for ZoomInfo Community Edition

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

DES Action

178 Columbus Avenue #237182

New York City, New York, 10023

United States

Company Description

DES Action USA has been serving the DES-exposed community since 1978 and welcomes health care providers who give services to DES-exposed individuals. Contact us to inquire about being named on our Physician Referral List. We urge health care providers to inc...more

Find other employees at this company (9)

Web References(52 Total References)


DES Action USA Staff | DES Action USA

Suzanne B. Robotti
Executive Director Suzanne Robotti founded MedShadow Foundation Inc. in 2012 after two major health issues drove her to become engaged in patient advocacy. Robotti's mother, like millions of other women in the 1950s and 1960s took the prescription drug DES (diethylstilbestrol), which was thought to prevent future miscarriages. The drug was widely used despite earlier publication of a study that linked DES to reproductive organ malformation and even cancer. DES was eventually taken off the market in 1971. When Robotti reached childbearing age herself, she discovered she was infertile due to DES exposure. This prompted her to join DES Action, a patient advocacy group. In 2010, her son's physician prescribed Ritalin for his ADD, but was unable to explain the medication's side effects. Robotti was concerned about the long-term effects of this stimulant on her son's developing brain.


DES Action USA Staff | DES Action USA

Suzanne B. Robotti
Executive Director Suzanne Robotti founded MedShadow Foundation Inc. in 2012 after two major health issues drove her to become engaged in patient advocacy. Robotti's mother, like millions of other women in the 1950s and 1960s took the prescription drug DES (diethylstilbestrol), which was thought to prevent future miscarriages. The drug was widely used despite earlier publication of a study that linked DES to reproductive organ malformation and even cancer. DES was eventually taken off the market in 1971. When Robotti reached childbearing age herself, she discovered she was infertile due to DES exposure. This prompted her to join DES Action, a patient advocacy group. In 2010, her son's physician prescribed Ritalin for his ADD, but was unable to explain the medication's side effects. Robotti was concerned about the long-term effects of this stimulant on her son's developing brain.


MedShadow FAQ - MedShadow

MedShadow Blog by Suzanne B. Robotti
Suzanne Robotti MedShadow Team Advisory Board Press Room A:Suzanne Robotti founded MedShadow Foundation in 2012 after two major health issues drove her to become engaged in patient advocacy. Robotti's mother, like millions of other women in the 1950s and 1960s, took the prescription drug DES (Diethylstilbestrol: a colorless crystalline synthetic compound C18H20O2 used as a potent estrogen but contraindicated in pregnancy for its tendency to cause cancer or birth defects in offspring -- called also DES, stilbestrol. --MedlinePlus" class="glossaryLink ">diethylstilbestrol), which was thought to prevent future miscarriages. The drug was widely used despite earlier publication of a study that linked DES to reproductive organ malformation and even cancer. DES was eventually taken off the market in 1971. When Robotti reached childbearing age herself, she discovered she was infertile due to DES exposure. This prompted her to join DES Action, a patient advocacy group. In 2010, her son's physician prescribed Ritalin for his attention deficit disorder (ADD), but was unable to explain the medication's side effects. Robotti was concerned about the long-term effects of this stimulant on her son's developing brain. These two experiences prompted Robotti to form MedShadow Foundation as a means of bringing the issue of medication side effects into the public discourse. A: MedShadow's founder, Suzanne Robotti, writes a weekly blog on a wide range of health topics, from the value of the Choose Wisely campaign that questions unnecessary medical procedures, to the need for more information on the safety of prescription and over-the-counter drugs during pregnancy.


About Suzanne Robotti - MedShadow

MedShadow Blog by Suzanne B. Robotti
Suzanne Robotti MedShadow Team Advisory Board Press Room About Suzanne Robotti Suzanne Robotti Suzanne Robotti founded MedShadow Foundation in 2012 after two major health issues drove her to become engaged in patient advocacy. Robotti's mother, like millions of other women in the 1950s and 1960s, took the prescription drug DES (Diethylstilbestrol: a colorless crystalline synthetic compound C18H20O2 used as a potent estrogen but contraindicated in pregnancy for its tendency to cause cancer or birth defects in offspring -- called also DES, stilbestrol. --MedlinePlus" class="glossaryLink ">diethylstilbestrol), which was thought to prevent future miscarriages. The drug was widely used despite earlier publication of a study that linked DES to reproductive organ malformation and even cancer. DES was eventually taken off the market in 1971. When Robotti reached childbearing age herself, she discovered she was infertile due to DES exposure. This prompted her to join DES Action USA, a patient advocacy group. In 2010, her son's physician prescribed Ritalin for his ADD, but was unable to explain the medication's side effects. This prompted concern about the long-term effects of this stimulant on her son's developing brain. These two experiences prompted Robotti to form MedShadow Foundation as a means of bringing the issue of medication side effects into the public discourse. In 2015, DES Action USA joined MedShadow Foundation after 30+ years as one of the most effective grass roots education and advocacy groups ever. DES Action's work continues as Robotti serves as executive director for the membership organization. In 2017, Robotti was named to the FDA Drug Safety and Risk Management Advisory Committee as the Consumer Representative. In addition to MedShadow, Robotti serves on the board of directors of New York City Community Board 7, the advisory board of Pace University's Masters in Publishing program, and is a trustee of Springfield College. Prior to founding MedShadow Foundation, she had a successful publishing industry career as founder first of Cradle Publishing and, later, Baby Publishing LLC which she later sold to Gruner+Jahr Bertelsmann. She holds a Bachelor of Arts degree in Communications from the University of Maryland at College Park. Robotti has been honored for her extensive contributions to community service from The President's Council on Service and Civic Participation. Follow Suzanne Robotti on Twitter @MedShadow_Su. Members of the media interested in interviewing Suzanne Robotti may contact Julie Livingston, Director, Communications at julie@medshadow.org.


About Suzanne Robotti - MedShadow

MedShadow Blog by Suzanne B. Robotti
Suzanne Robotti MedShadow Team Advisory Board Press Room About Suzanne Robotti Suzanne Robotti Suzanne Robotti founded MedShadow Foundation in 2012 after two major health issues drove her to become engaged in patient advocacy. Robotti's mother, like millions of other women in the 1950s and 1960s, took the prescription drug DES (Diethylstilbestrol: a colorless crystalline synthetic compound C18H20O2 used as a potent estrogen but contraindicated in pregnancy for its tendency to cause cancer or birth defects in offspring -- called also DES, stilbestrol. --MedlinePlus" class="glossaryLink ">diethylstilbestrol), which was thought to prevent future miscarriages. The drug was widely used despite earlier publication of a study that linked DES to reproductive organ malformation and even cancer. DES was eventually taken off the market in 1971. When Robotti reached childbearing age herself, she discovered she was infertile due to DES exposure. This prompted her to join DES Action USA, a patient advocacy group. In 2010, her son's physician prescribed Ritalin for his ADD, but was unable to explain the medication's side effects. This prompted concern about the long-term effects of this stimulant on her son's developing brain. These two experiences prompted Robotti to form MedShadow Foundation as a means of bringing the issue of medication side effects into the public discourse. In 2015, DES Action USA joined MedShadow Foundation after 30+ years as one of the most effective grass roots education and advocacy groups ever. DES Action's work continues as Robotti serves as executive director for the membership organization. In 2017, Robotti was named to the FDA Drug Safety and Risk Management Advisory Committee as the Consumer Representative. In addition to MedShadow, Robottiserves on the board of directors of New York City Community Board 7, the advisory board of Pace University's Masters in Publishing program, and is a trustee of Springfield College. Prior to founding MedShadow Foundation, she had a successful publishing industry career as founder first of Cradle Publishing and, later, Baby Publishing LLC which she later sold to Gruner+Jahr Bertelsmann. She holds a Bachelor of Arts degree in Communications from the University of Maryland at College Park. Robotti has been honored for her extensive contributions to community service from The President's Council on Service and Civic Participation. Follow Suzanne Robotti on Twitter @MedShadow_Su. Members of the media interested in interviewing Suzanne Robotti may contact Julie Livingston, Director, Communications at julie@medshadow.org.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory